Pentadecapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
In 1946, Freeman performed this procedure for the first time on a patient, who was subdued before the operation with electroshock treatment. The transorbital lobotomy procedure, which Freeman performed very quickly, sometimes in less than 10 minutes, was used on many patients with relatively minor mental disorders that Freeman believed did not warrant traditional lobotomy surgery, in which the skull itself was opened. A large proportion of such lobotomized patients exhibited reduced tension or agitation. Many also showed other effects, such as apathy, passivity, lack of initiative, poor concentration, and a generally decreased depth and intensity of their emotional response to life. Some died as a result of the procedure. However, those effects were not widely reported in the 1940s, and at that time, the long-term effects were largely unknown. Because the procedure met with seemingly widespread success, Moniz was awarded the 1949 Nobel Prize for Physiology or Medicine (along with Swiss physiologist Walter Rudolf Hess). Lobotomies were performed on a wide scale during the 1940s; Freeman himself performed or supervised more than 3,500 lobotomies by the late 1960s. Freeman performed his first transorbital lobotomy on Ellen Ionesco, a woman who suffered from bouts of manic depression and suicidal ideation. Freeman utilized media coverage and penned editorials for numerous interviews promoting the procedure and achieving accolades for his work in psychiatric care.
Cava (stylized in all caps as CAVA) is an American Mediterranean fast casual restaurant chain with locations across the United States. Cava is owned by the publicly traded Cava Group, which purchased Zoës Kitchen in August 2018. The combined company is the largest restaurant operator in the Mediterranean category in the U.S. restaurant industry. Cava also produces a line of Mediterranean cava dips, spreads, and dressings that are sold in grocery stores across the US. As of May 2023, all Zoës Kitchen restaurants have been closed or replaced by Cava restaurants.
Glutamate is used at the great majority of fast excitatory synapses in the brain and spinal cord. It is also used at most synapses that are "modifiable", i.e. capable of increasing or decreasing in strength. Modifiable synapses are thought to be the main memory-storage elements in the brain. Excessive glutamate release can overstimulate the brain and lead to excitotoxicity causing cell death resulting in seizures or strokes. Excitotoxicity has been implicated in certain chronic diseases including ischemic stroke, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington disease, and Parkinson's disease. GABA is used at the great majority of fast inhibitory synapses in virtually every part of the brain. Many sedative/tranquilizing drugs act by enhancing the effects of GABA. Glycine is the primary inhibitory neurotransmitter in the spinal cord. Acetylcholine was the first neurotransmitter discovered in the peripheral and central nervous systems. It activates skeletal muscles in the somatic nervous system and may either excite or inhibit internal organs in the autonomic system. It is the main neurotransmitter at the neuromuscular junction connecting motor nerves to muscles. The paralytic arrow-poison curare acts by blocking transmission at these synapses. Acetylcholine also operates in many regions of the brain as neuromodulatory, but uses different types of receptors, including nicotinic and muscarinic receptors. Dopamine has a number of important functions in the brain. This includes critical role in the reward system, motivation and emotional arousal.
The city's main opera house is Teatro Regio di Torino, where Puccini premiered his La bohème in 1896. It was burned down in 1936 and was rebuilt after World War II. On 8 October 2021, the European Broadcasting Union (EBU) and RAI announced that the city would host the Eurovision Song Contest 2022, following Italy's victory at the 2021 contest in Rotterdam, Netherlands, with the song "Zitti e buoni", performed by Måneskin. The contest took place at the Pala Alpitour, with both semi-finals of the contest took place on 10 and 12 May, and the grand final on 14 May. It was the first time that Turin has hosted the contest and the third time that Italy has hosted the contest overall, with the last being in Rome in 1991.
== Working with FASTA files == A plethora of user-friendly scripts are available from the community to perform FASTA file manipulations. Online toolboxes, such as FaBox or the FASTX-Toolkit within Galaxy servers, are also available. These can be used to segregate sequence headers/identifiers, rename them, shorten them, or extract sequences of interest from large FASTA files based on a list of wanted identifiers (among other available functions). A tree-based approach to sorting multi-FASTA files (TREE2FASTA) also exists based on the coloring and/or annotation of sequences of interest in the FigTree viewer. Additionally, the Bioconductor Biostrings package can be used to read and manipulate FASTA files in R. Several online format converters exist to rapidly reformat multi-FASTA files to different formats (e.g. NEXUS, PHYLIP) for use with different phylogenetic programs, such as the converter available on phylogeny.fr.
Sources: en.wikipedia.org
International Chemical Safety Card 1262 (2-methylpentane) Material Safety Data Sheet for Hexane National Pollutant Inventory – n-hexane fact sheet Phytochemica l database entry Center for Disease Control and Prevention Warning from National Safety Council "COMMON CHEMICAL AFFECTS AUTO MECHANICS" Australian National Pollutant Inventory (NPI) page "EPA does not consider n-hexane classifiable as a human carcinogen." Federal Register / Vol. 66, No. 71 / Thursday, 12 April 2001 / Rules and Regulations
== Other ventures == On "Double Cup", an episode of FXX's Major Lazer, he made a guest appearance as Double Cup, The Codeine Scientist. Riff Raff competed on a special for the MTV reality series The Challenge, premiering November 21, 2017, and titled Champs vs. Stars. On February 15, 2012, film director Harmony Korine contacted Riff Raff about appearing in an upcoming movie of his, which would turn out to be Spring Breakers. Once the details of the movie came out, there was speculation that the main character Alien was based on Riff Raff. However, according to James Franco, his character was based on the underground rap artist Dangeruss. He said "Of course Harmony and I looked at some of Riff Raff's videos as inspiration, but he was one of a number of people we looked at. I would say the biggest influence on the role was this local Florida rapper named Dangeruss. He's fairly unknown, but he was down there in the place, living the life, and he became the biggest model for me, and he's in the movie." There was much back and forth between both camps about the issue, including Riff Raff appearing in a cameo for One Life to Live playing a character called "Jamie Franko". In July 2013, Riff Raff announced he was suing the creators of Spring Breakers for $10 million for using his image without permission. However, a search for court documents by LA Weekly in September 2013 resulted in no findings. In 2017, Riff Raff partnered with Reef Dispensaries to develop and endorse two new strains of marijuana.
=== Continuous glucose monitoring === The clinical role of continuous glucose monitoring (CGM) is unclear. Comparing results of CGM studies is problematic as study parameters are non-standardized. The IFCC supported a review to provide recommendations that encourage developing standards for CGM performance studies.
=== Effects on health === The US Food and Drug Administration has determined there is little credible evidence that tomatoes or tomato-based foods reduce the risk of various types of cancer. In a 2011 scientific review, the European Food Safety Authority concluded that lycopene did not favorably influence DNA, skin exposed to ultraviolet radiation, heart function or vision.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.